Company intelligence / Profile preview

Selexis

Plan-les-Ouates/Geneva, Geneva, Switzerlandselexis.com ↗
Ownership
Private
Employees
~53
Development stage
Other
01

Overview

Selexis pioneered mammalian cell line generation with its SUREtechnology Platform™, enabling rapid and stable production of recombinant proteins. Its technologies are used by global biopharmaceutical partners to accelerate the discovery, development, and commercialization of biologics and vaccines. Over ten commercial products use Selexis-derived cell lines; more than one hundred sixty drug candidates developed using their platforms are at various stages from preclinical to clinical trials. The company was acquired by JSR Life Sciences in 2017 and integrated into KBI Biopharma operations in 2023 to provide end-to-end CDMO services.

Therapeutic areas
Metabolic DisordersImmunologyDermatologyHematologyOncology
Modalities
Recombinant proteinMonoclonal antibodyBiologicVaccine
Industry
Contract Manufacturing Organization
02

Partnerships

Over one hundred global biopharmaceutical partners utilizing the SUREtechnology Platform™ for drug development; specific names not disclosed publicly.

Beyond the preview

Go deeper on Selexis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selexis.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call